Mechanism of action
Retatrutide is a single peptide that activates the GIP, GLP-1 and glucagon receptors. GIP and GLP-1 act on insulin release and appetite, as with tirzepatide. The glucagon action is thought to raise energy use and reduce liver fat. Because of the three targets, retatrutide is often called a triple agonist. Like tirzepatide, it is a peptide given as a weekly injection under the skin, and the trials raised the dose step by step.
Clinical trials
Retatrutide was first tested for obesity in a 48-week phase 2 trial of 338 adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition. In its phase 2 trial, people on the highest dose of retatrutide (12 mg) lost 24.2% of their weight on average after 48 weeks, vs. 2.1% on placebo. In that trial, heart rate rose with the dose, peaked at 24 weeks and then declined.
The phase 3 program is called TRIUMPH. TRIUMPH-1 enrolled 2,339 adults with obesity or overweight and compared 4 mg, 9 mg and 12 mg doses with placebo for 80 weeks. It also included smaller groups of people with knee osteoarthritis pain or obstructive sleep apnea. In the phase 3 TRIUMPH-1 trial, adults with obesity or overweight on the 12 mg dose of retatrutide lost 25.0% of their body weight on average after 80 weeks, vs. 3.9% on placebo. Other TRIUMPH trials studied people with type 2 diabetes and people with heart disease, and one trial, TRIUMPH-5, compares retatrutide with tirzepatide directly.
The most common side effects in trials were stomach-related, such as nausea, and were more frequent at higher doses. Some participants reported dysesthesia, an abnormal skin sensation.
Regulatory status
As of November 2026, retatrutide is not approved by the FDA for any use. Lilly has said it plans to submit an application to the FDA in the first quarter of 2027. Until a decision, retatrutide is available only in clinical trials or, for a small number of patients who meet Lilly's criteria and cannot join a trial, through a physician-requested expanded access program that opened in August 2026 (NCT07629401). Products sold online as retatrutide are not approved medicines. If it is approved, retatrutide would be the first medicine on the US market to act on three hormone receptors.
Our retatrutide page tracks its status and lists the approved medicines people use now.
Timeline
- 2023-06-26Phase 2 obesity results published in NEJM
- 2026-05-21Lilly reports topline results of the TRIUMPH-1 phase 3 trial
- 2026-09-29TRIUMPH-1 published in NEJM
See retatrutide status and current options
See also
References
- Jastreboff et al., NEJM 2023 (retatrutide phase 2). pubmed.ncbi.nlm.nih.gov
- TRIUMPH-1, NEJM 2026 (retatrutide phase 3). pubmed.ncbi.nlm.nih.gov
- TRIUMPH-1 study record, NCT05929066, ClinicalTrials.gov. clinicaltrials.gov
- TRIUMPH-5 study record, NCT06662383, ClinicalTrials.gov. clinicaltrials.gov
- Eli Lilly press release on TRIUMPH-2 and TRIUMPH-3, July 23, 2026
- Retatrutide expanded access program, NCT07629401, ClinicalTrials.gov. clinicaltrials.gov
Last updated . Category: Medications. Browse all 38 WikiTelehealth entries.